| 17.92 -0.05 (-0.28%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.47 | 1-year : | 25.08 |
| Resists | First : | 18.38 | Second : | 21.47 |
| Pivot price | 17.41 |
|||
| Supports | First : | 16.74 | Second : | 15.73 |
| MAs | MA(5) : | 17.84 |
MA(20) : | 17.35 |
| MA(100) : | 14.06 |
MA(250) : | 12.49 |
|
| MACD | MACD : | 0.6  |
Signal : | 0.6 |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 73 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 18.38 | Low : | 7.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMRX ] has closed below upper band by 22.7%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.23 - 18.32 | 18.32 - 18.4 |
| Low: | 17.58 - 17.7 | 17.7 - 17.8 |
| Close: | 17.75 - 17.93 | 17.93 - 18.08 |
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Fri, 24 Jul 2026
ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks - TradingView
Mon, 20 Jul 2026
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha
Sat, 18 Jul 2026
Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
Thu, 16 Jul 2026
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating? - Sahm
Mon, 13 Jul 2026
Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 319 (M) |
| Shares Float | 178 (M) |
| Held by Insiders | 49 (%) |
| Held by Institutions | 52.2 (%) |
| Shares Short | 7,840 (K) |
| Shares Short P.Month | 7,530 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.15 |
| Profit Margin | 4 % |
| Operating Margin | 19.5 % |
| Return on Assets (ttm) | 8.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 3.72 |
| Sales Per Share | 9.55 |
| EBITDA (p.s.) | 2.09 |
| Qtrly Earnings Growth | 384.6 % |
| Operating Cash Flow | 306 (M) |
| Levered Free Cash Flow | 101 (M) |
| PE Ratio | 48.43 |
| PEG Ratio | 0 |
| Price to Book value | -128 |
| Price to Sales | 1.87 |
| Price to Cash Flow | 18.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|